Table 3.
Effectiveness: Outcomes of immunosuppressive therapy for specific diseases.
| Disease | % of patients with disease control | % of patients in remission | % decrease in number of patients with vision loss to ≤20/200 | % decrease in incidence of complications |
|---|---|---|---|---|
| Behçet’s disease | 50—89% 5,14,15,16 | |||
| Serpiginous choroidopathy | 75% 17 | |||
| Birdshot chorioretinopathy | 82% decrease in CME 18 | |||
| 100% with reversal of VF loss 19 | ||||
| MFCPU | 90% 20 | 83% decrease in overall complications 20 100% decrease in new CNV or optic neuropathy 21 |
||
| Chronic VKH | 92% 22 | |||
| MMP | 83% by 6 mo 3 | 91%by2y 3 |
CME = cystoid macular edema; CNV = choroidal neovascularization; MFCPU = multifocal choroiditis and panuveitis; MMP = mucous membrane pemphigoid; VF = visual field; VKH = Vogt—Koyanagi—Harada syndrome.